Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Either A or B below and who were not adequately controlled with their lipid-modifying therapy:~A) Participants with heterozygous familial hypercholesterolemia (heFH) with or without established coronary heart disease (CHD) or CHD risk equivalents~OR~B) Participants with hypercholesterolemia together with established CHD or CHD risk equivalents.~Exclusion criteria:~* Age \< 18 years~* LDL-C \<70 mg/dL (\< 1.81 mmol/L)~* Fasting serum triglycerides \> 400 mg/dL (\>4.52 mmol/L)~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
- Alirocumab (Type: EXPERIMENTAL): Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).